Education
About Us
Working with TipRanks
Follow Us
Apogee Therapeutics (APGE)
NASDAQ:APGE
APGE Stock Chart & Stats
$62.13
-$0.82(-1.65%)
At close: 4:00 PM EST
$62.13
-$0.82(-1.65%)
Day’s Range― - ―
52-Week Range$26.20 - $84.56
Previous CloseN/A
Volume109.80K
Average Volume (3M)991.25K
Market Cap
$4.47B
Enterprise Value$3.36B
Total Cash (Recent Filing)$527.29M
Total Debt (Recent Filing)$9.85M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Mar 10, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding54,833,588
10 Day Avg. Volume1,024,348
30 Day Avg. Volume991,246
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)3.49
Price to Sales (P/S)0.00
P/FCF Ratio-14.51
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.40K
Enterprise Value/Ebitda-12.17
Forecast
1Y Price Target
$105.67Price Target Upside70.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.88
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementAnalyst highlights that zumilokibart's progression into later-stage clinical trials positions the company ahead of peers and could improve the stock if trials confirm stronger clinical benefit.
Efficacy And Dosing DifferentiationAnalyst notes phase 1b asthma results showed durable reduction in a key biomarker and lung-function improvements, supporting the potential for less frequent dosing and dual labeling for asthma and atopic dermatitis.
Pipeline Strategy And Upcoming ReadoutsAnalyst points to upcoming long-term, induction, and head-to-head readouts plus the APG279 combination targeting two immune pathways as catalysts that could materially increase company value if positive.
Bears Say
Limited Dataset And ConfidenceAnalyst cautions that the small Phase 1b sample size and imbalance in background asthma medications limit confidence in the trial's efficacy and safety conclusions.
Research ObjectivityAnalyst disclosure notes potential conflicts of interest at the firm that could influence research objectivity and affect how investors interpret the recommendation.
Safety And Class RiskAnalyst warns that a reported cancer case linked to a T-cell–affecting therapy could be drug-related and might raise broader class-safety concerns for similar programs.
Apogee Therapeutics News
APGE FAQ
What was Apogee Therapeutics’s price range in the past 12 months?
Apogee Therapeutics lowest stock price was $26.20 and its highest was $84.56 in the past 12 months.
What is Apogee Therapeutics’s market cap?
Apogee Therapeutics’s market cap is $4.47B.
When is Apogee Therapeutics’s upcoming earnings report date?
Apogee Therapeutics’s upcoming earnings report date is Mar 10, 2026 which is in 26 days.
How were Apogee Therapeutics’s earnings last quarter?
Apogee Therapeutics released its earnings results on Nov 10, 2025. The company reported -$1.11 earnings per share for the quarter, beating the consensus estimate of -$1.175 by $0.065.
Is Apogee Therapeutics overvalued?
According to Wall Street analysts Apogee Therapeutics’s price is currently Undervalued.
Does Apogee Therapeutics pay dividends?
Apogee Therapeutics does not currently pay dividends.
What is Apogee Therapeutics’s EPS estimate?
Apogee Therapeutics’s EPS estimate is -1.05.
How many shares outstanding does Apogee Therapeutics have?
Apogee Therapeutics has 54,833,588 shares outstanding.
What happened to Apogee Therapeutics’s price movement after its last earnings report?
Apogee Therapeutics reported an EPS of -$1.11 in its last earnings report, beating expectations of -$1.175. Following the earnings report the stock price went up 3.765%.
Which hedge fund is a major shareholder of Apogee Therapeutics?
Currently, no hedge funds are holding shares in APGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Apogee Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$105.67 (70.08% Upside)
$105.67 (70.08% Upside)
Blogger Sentiment
Bullish
APGE Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 776.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $133.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.41%
12-Months-Change
Fundamentals
Return on Equity
-38.41%
Trailing 12-Months
Asset Growth
-19.34%
Trailing 12-Months
Company Description
Apogee Therapeutics
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
APGE Stock 12 Month Forecast
Average Price Target
$105.67
▲(70.08% Upside)
Technical Analysis
Agios Pharma
―
Ocular Therapeutix
―
Galapagos
―
Liquidia Technologies
―
IDEAYA Biosciences
―
Ownership Overview
Currently, No data available
---